Metabolic & Weight Loss
Pramlintide
Symlin; SymlinPen
1 min read · Updated July 27, 2026 · 3 references
Curated by PeptideInfo Wikilast reviewed how we verify
An approved amylin analog used with mealtime insulin in selected adults with type 1 or type 2 diabetes.
Evidence: Regulator-approved drug with human trial evidence.
Approved in: FDA (United States; adjunct to mealtime insulin)
- An approved amylin analog used with mealtime insulin in selected adults with type 1 or type 2 diabetes.
- It complements insulin by suppressing post-meal glucagon, slowing gastric emptying and increasing satiety.
- The boxed warning concerns severe insulin-induced hypoglycemia, especially in type 1 diabetes; careful patient selection and insulin adjustment are central to the label.
An approved amylin analog used with mealtime insulin in selected adults with type 1 or type 2 diabetes.
Overview
An approved amylin analog used with mealtime insulin in selected adults with type 1 or type 2 diabetes.
Primary regulatory source
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.
Identity and mechanism
It complements insulin by suppressing post-meal glucagon, slowing gastric emptying and increasing satiety.
PubChem CID 70691388; C171H267N51O53S2; 3949 Da.
Regulatory label facts
FDA (United States; adjunct to mealtime insulin).
The dose below reproduces a regulator-approved label; it is not a treatment recommendation. The label starts at 15 micrograms before major meals in type 1 diabetes and 60 micrograms before major meals in type 2 diabetes, with simultaneous 50% mealtime-insulin reduction and label-defined titration.
Safety boundary
The boxed warning concerns severe insulin-induced hypoglycemia, especially in type 1 diabetes; careful patient selection and insulin adjustment are central to the label.
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.
References
Frequently asked questions
- What is Pramlintide?
- An approved amylin analog used with mealtime insulin in selected adults with type 1 or type 2 diabetes.
- Is Pramlintide approved as a medicine, and where?
- It is an approved prescription medicine, but where it is approved matters: FDA (United States; adjunct to mealtime insulin). It should only be used under medical supervision.
- What is Pramlintide studied for?
- Pramlintide is most often discussed in the context of approved peptide medicines — verification pilot. Being studied for an area does not mean it is proven or approved for it.
- Does Pramlintide have human clinical trials?
- Yes. Pramlintide has been studied in human clinical trials and is an approved medicine in at least some regions.
Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Pramlintide is an approved medicine within the stated approval scope (FDA (United States; adjunct to mealtime insulin)) and must only be used under medical supervision; research-grade or unprescribed material is not a lawful substitute. Consult a qualified healthcare professional before making health decisions.